



**meetings
in a box**

ROAD TO **ESMO 2026**

A cura di Annalice Gandini, Parigi (FR)

GASTROINTESTINAL CANCER – Colorectal cancer

LOCALIZED DISEASE

- **IROCAS (Bennouna – LBA29)**
A randomized phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in **high-risk stage III** (T₄ and/or N₂) colon cancer
- **AZUR-1 (Cercek – LBA87)**
Clinical complete response with dostarlimab monotherapy in **dMMR/MSI-H** locally advanced rectal cancer (LARC): First results from the global registrational AZUR-1 Trial
- **UNION (Lin – Abstract 3530O)**
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in **locally advanced rectal cancer (LARC)**: the phase 3 UNION trial → positive in 3y-EFS (91.3% vs 77.4%, HR=0.33; p=0.0029)
- **MONSTAR-SCREEN-3 (Tsukada – Abstract 4236O)**
Clinical significance of ultrasensitive ctDNA Detection for molecular residual disease assessment in resectable colorectal cancer in MONSTAR-SCREEN-3 ▯ WGS-based ctDNA: pre-recurrence ctDNA was detectable in all 23 recurrence cases (100%; median lead 4.0 months)

GASTROINTESTINAL CANCER – Colorectal cancer

ADVANCED DISEASE

- **CheckMate 8HW (Lonardi – LBA32)**

Final overall survival results from CheckMate 8HW: Nivolumab plus ipilimumab versus nivolumab or chemotherapy in **MSI-H/dMMR** metastatic colorectal cancer

- **PRABITAS (Taniguchi – LBA31)**

Biweekly versus conventional **trifluridine/tipiracil plus bevacizumab** for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trial

GASTROINTESTINAL CANCER – Other GI cancers

GASTRIC/GEJ CANCER

- **CLARITY-Gastric 01 (Xu – LBA7)**
A Phase 3 study of sonesitug vedotin (Sone-Ve) in second or later-line (≥L+) advanced or metastatic **Claudin 18.2 (CLDN18.2) positive** gastroesophageal carcinoma (GEC)
- **HERIZON-GEA-01 (Shitara – LBA79)**
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) **HER2-positive (HER2+)** advanced/mets gastroesophageal adenocarcinoma (mGEA): Second interim analysis from HERIZON-GEA

OESOPHAGEAL CANCER

- **SANO (Gangaram-Panday – LBA78)**
Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: Long-term results of a cluster-randomised controlled trial (SANO)

BILIARY TRACT CANCER

- **HARMONi-GI1 (Zhou – LBA8)**
Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: A randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1)
- **ACTICCA-1 (Wege – LBA21)**
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and gallbladder carcinoma (ACTICCA-1 trial)

BREAST CANCER

LOCALIZED DISEASE

- **NATALEE (Slamon – LBA25)**

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with **HR+/HER2–** early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

- **NSABP B-42 (Mamounas – LBA24)**

Final analysis of NRG Oncology/NSABP B-42, a randomized, double-blinded, placebo-controlled trial of extended letrozole in postmenopausal women with **hormone-receptor positive** breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor

- **TALENT (Hurvitz – LBA23)**

Final results of TALENT: A **neoadjuvant** trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for **HER2-low, HR+** early-stage breast cancer

BREAST CANCER

ADVANCED DISEASE

- **KEYNOTE-B49 (Rugo – LBA51)**

A Phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants with **HR+/HER2–** advanced breast cancer (ABC) → *previously progressed to endocrine therapy*

- **FINER / MA.40 (Redfern – LBA14)**

A double-blind placebo controlled randomized Phase III Trial of fulvestrant and ipatasertib (*AKT inhibitor*) as treatment for HER-2 negative and **estrogen receptor positive (ER+)** metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/FINER Study (NCT04650581) → *already positive in PFS*

- **postMONARCH (Kalinsky – Abstract 1RO)**

Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for **HR+, HER2–** advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy → *368 patients. mOS 32.1 vs 24.6 months; p=0.1145*)

BREAST CANCER

ADVANCED DISEASE

- **VIKTORIA-1 (Pistilli – LBA16)**

Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) (*PI3K/AKT/mTOR inhibitor*) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with **HR+/HER2–** advanced breast cancer (ABC) (Study 2)

- **PANKU-Breast01 (Lan – LBA50)**

Randomized Phase III study of izalontamab brengitecan (iza-bren) (*bispecific ADC anti-EGFR × anti-HER3*) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (**HR+/HER2–**) breast cancer (BC)

- **HORIZON-Breast06 (Fan – LBA13)**

Trastuzumab rezetecan (SHR-A1811) in **HER2-low** advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)

LUNG CANCER

ADVANCED DISEASE - NSCLC

- **Krascendo 1 (Skoulidis – LBA5)**

Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic **KRAS G12C-mutated** NSCLC

- **SAFFRON (Lu – LBA6)**

Osimertinib (osi) + savolitinib (savo) (*TKI anti-MET*) vs platinum–pemetrexed (plat–pem) in **EGFRm MET-overexpressed (OE) and/or -amplified (AMP)** advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results → *Pre-treated vs CT*

- **SANOVO (Wu – LBA69)**

Savolitinib or placebo combined with osimertinib in treatment-naïve advanced NSCLC with **EGFR mutation and MET overexpression**: Results from the Phase 3 SANOVO Study → *1 line*

- **HERON-Lung01 (Wu – LBA72)**

Ruzaltatug rezetecan, a HER3-directed ADC, vs platinum-based chemotherapy (PBC) in **EGFR-mutated** advanced NSCLC progressing after EGFR-TKI: Interim analyses (IA) from the phase 3 HERON-Lung01 trial

- **OptiTROP-Lung06 (Zhou – LBA66)**

Sacituzumab tirumotecan (sac-TMT) (*ADC anti-TROP2*) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for **PD-L1 negative** advanced non-squamous (nsq) NSCLC: Randomized phase 3 OptiTROP-Lung06 study

LUNG CANCER

LOCALIZED DISEASE - NSCLC

- **Neotorch (Lu – LBA64)**

Toripalimab (anti PD-1) plus chemotherapy as perioperative treatment for resectable stage II or III non-small cell lung cancer (NSCLC): Final analysis of the Phase 3 Neotorch study [\[1\]](#) already positive in pCR and EFS

OTHER LUNG CANCERS

- **DeLLphi-305 (Sands – LBA3)**

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

GENITOURINARY CANCERS

PROSTATE CANCER

- **DASL-HiCaP (Niazi – LBA4)**

Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, **very high-risk** prostate cancer: interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)

- **PEACE-1 (Fizazi – Abstract 2215O)**

Long-term overall survival with abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial for **de novo metastatic castration-sensitive** prostate cancer (mCSPC) → *OS benefit of abiraterone + SOC irrespective of metastatic extent*

- **CAPItello-281 (Fizazi – LBA56)**

Capivasertib (capi) (*AKT inhibitor*) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with **PTEN-deficient** metastatic hormone sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281

GENITOURINARY CANCERS

UROTHELIAL CANCER

- **VOLGA (Powles – LBA2)**

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in **muscle-invasive bladder cancer**: Results from the Phase 3 VOLGA trial

- **KEYNOTE-866 (Bedke – Abstract 4735O)**

Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with **muscle-invasive bladder cancer (MIBC)**: The double-blind, phase 3 KEYNOTE-866 study → *negative in EFS*

GENITOURINARY CANCERS

RENAL CELL CARCINOMA

- **LITESPARK-012 (Choueiri – Abstract 3586O)**
First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A (*coformulated quavonlimab [anti-CTLA-4]/pembrolizumab*) + lenvatinib in advanced RCC: Randomized open-label phase 3 LITESPARK-012 study → *negative*
- **LITESPARK-011 (Heng – Abstract 3587O)**
Final analysis of the phase 3 LITESPARK-011 study: Belzutifan + lenvatinib versus cabozantinib for advanced RCC **after anti-PD-(L)1 therapy** → *already positive in PFS and ORR, OS favored but not statistically significant*
- **KEYNOTE-564 (Choueiri – Abstract 3589RO)**
Final protocol-prespecified analysis of the phase 3 KEYNOTE-564 trial of **adjuvant** pembrolizumab versus placebo in clear cell renal cell carcinoma (ccRCC) → *confirmed efficacy*

GYNECOLOGIC CANCERS

ENDOMETRIAL CANCER

- **TroFuse-005 (Lorusso – LBA11)**

Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study

- **KEYNOTE-C93 (Slomovitz – LBA12)**

Phase 3, randomized, open-label study of first-line (1L) pembrolizumab (pembro) vs carboplatin (C) + paclitaxel (P) in **mismatch repair-deficient (dMMR)** advanced or recurrent endometrial carcinoma (a/rEC)

- **DUO-E (Westin – LBA37)**

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised Phase 3 DUO-E/GOG-3041/ENGOT-EN10 study

CERVICAL CANCER

- **BEATcc (Oaknin – LBA38)**

Final overall survival (OS) results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC)

OTHER CANCERS

- **Melanoma (Long – LBA1)**

INTerpath-001: Phase 3 study of the **mRNA-based individualized neoantigen therapy** (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)

- **Melanoma (Witteveen – Abstract 2076RO)**

Three-year distant metastasis-free survival of the phase 3 NADINA trial comparing **neoadjuvant** nivolumab plus ipilimumab versus adjuvant nivo in resectable stage III melanoma

- **Cutaneous squamous cell carcinoma (Rischin – LBA59)**

C-POST phase 3 trial of adjuvant (adj) cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC): Updated overall survival (OS) and outcomes from circulating tumour DNA (ctDNA) analyses

- **Osteosarcoma (Xie – LBA9)**

Risvutatug rezetecan (Ris-Rez) versus gemcitabine and docetaxel (GD) in heavily pretreated patients (pts) with relapsed or refractory (R/R) osteosarcoma: Primary results from the Phase 3 ARTEMIS-011 Study

OTHER CANCERS

- **GIST (Jones – Abstract 3717RO)**

Phase 3 Peak crossover: Bezuclastinib (*KIT inhibitor*) + sunitinib combination following sunitinib monotherapy in patients with GIST

- **Nasopharyngeal carcinoma (Hong – LBA43)**

Tam-Peli (*tambotatug pelitecan* (YL201); *ADC anti-B7-H3*) versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, randomized, open-label, phase 3 study (TAISHAN-301)

- **Multicancer (Gravis – LBA10)**

MOIO: Interim analyses of a Phase III randomized non inferiority trial assessing **reduced frequency immune checkpoint inhibitors** in responding patients with advanced/metastatic cancer → *the same IO administered each 3 months in patients in response after 6 months of standard IO*